Abstract: The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions for use in methods for treatment, in particular for use in the treatment of periodontitis and related conditions; as well as to crystals comprising bacterial glutaminyl cyclases, methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors.

Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.

Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.

Abstract: The present disclosure generally relates to therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells may be generated in vitro/ex vivo as well as in vitro by delivering nucleic acid encoding an antigen receptor for genetic modification to cells using particles comprising the nucleic acid and a targeting molecule for targeting the immune effector cells, wherein the targeting molecule is a designed ankyrin repeat protein (DARPin). In particular, DARPins are described herein which are high-affinity binders for CDS binding to the CDS receptor on human and non-human primate (NHP) cells. Nanoparticles functionalized with CD8? targeting DARPins (CDS-DARPin) can deliver genes exclusively and specifically to human CD8+ T cells in vitro and in vivo.

Abstract: The present invention provides a composition comprising i) a pseudotyped retroviral vector particle comprising a) one envelope protein with antigen-binding activity, wherein said envelope protein is a recombinant protein that does not interact with at least one of its original receptors and is fused at its ectodomain to a polypeptide comprising an antigen binding domain specific for CD62L, and wherein said envelope protein is protein G, HN or H derived from the Paramyxoviridae family, b) one envelope protein with fusion activity derived from the Paramyxoviridae family, and T cells expressing CD62L. Alternatively, when said polypeptide comprising an antigen binding domain is specific for a tag of a tagged polypeptide instead of the antigen binding domain specific for CD62L, wherein said tagged polypeptide binds specifically to CD62L, then the composition comprises further said tagged polypeptide.

Abstract: The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus Morbillivirus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation of morbillivirus F and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.

Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.

Abstract: The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus Morbillivirus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation of morbillivirus F and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Alzheimer's disease. In particular the present invention relates to a method of treating Alzheimer's disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for a polypeptide which is a soluble member of the APP (amyloid precursor protein) family.

Abstract: A piece of seating furniture having at least one base body, at least one adjustable functional part, at least one pivot fitting for adjusting the functional part relative to the base body and a separate, lift setting mechanism for locking the functional part in relation to the base body. The lift setting mechanism has a guide and a slender bar which can be moved in relation to the guide. The lift setting mechanism can be moved from a set position, blocking the adjustment of the functional part, to a reset position, unblocking the adjustment of the functional part. The pivoted lever is pivotably connected to the base body separately via two adjusting levers, the two adjusting levers are jointly connected to the base body via a control lever and one adjusting lever is pivotably connected to the base body via a guide lever.

Abstract: The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus Morbillivirus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation of morbillivirus F and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.

Abstract: A pivot fitting having a stop lever, a ratchet lever, a blocking device and at least one toothed ring. The stop lever and the ratchet lever can be pivoted in relation to one another in an adjustment direction and in a reset direction. The stop lever and the toothed ring are coupled to one another such that pivoting of the stop lever and ratchet lever in the adjustment direction is accompanied by pivoting and/or rotation of the toothed ring in relation to the blocking device. The blocking device has at least two catches, that, in an adjustment position of the pivot fitting, the pivoting action of the stop lever and ratchet lever in the reset direction is countered by form-fitting engagement of at least one catch in the toothed ring.

Abstract: A piece of seating furniture having at least one base body, at least one adjustable functional part, at least one pivot fitting for adjusting the functional part relative to the base body and a separate, lift setting mechanism for locking the functional part in relation to the base body. The lift setting mechanism has a guide and a slender bar which can be moved in relation to the guide. The lift setting mechanism can be moved from a set position, blocking the adjustment of the functional part, to a reset position, unblocking the adjustment of the functional part. The pivoted lever is pivotably connected to the base body separately via two adjusting levers, the two adjusting levers are jointly connected to the base body via a control lever and one adjusting lever is pivotably connected to the base body via a guide lever.

Abstract: A pivot fitting having a stop lever, a ratchet lever, a blocking device and at least one toothed ring. The stop lever and the ratchet lever can be pivoted in relation to one another in an adjustment direction and in a reset direction. The stop lever and the toothed ring are coupled to one another such that pivoting of the stop lever and ratchet lever in the adjustment direction is accompanied by pivoting and/or rotation of the toothed ring in relation to the blocking device. The blocking device has at least two catches, that, in an adjustment position of the pivot fitting, the pivoting action of the stop lever and ratchet lever in the reset direction is countered by form-fitting engagement of at least one catch in the toothed ring.

Abstract: The inventors developed novel pseudotyped lentiviral vector particles comprising a morbillivirus fusion (F) protein and a mutated hemagglutinin (H) protein of the measles virus (MeV) or the Edmonton strain of the measles virus (MeVEdm), wherein the cytoplasmic portions of the F and the H protein are truncated, and wherein the amino acids necessary for receptor recognition in the H protein are mutated that it does not interact with CD46, SLAM and/or nectin-4 and further has a single chain antibody to a cell surface marker of hESCs and iPSCs at its ectodomain. In this invention, the single chain variable fragment (scFv) anti-cell surface marker coding sequence of the single chain antibody is fused to the coding sequence at the ectodomain of the H protein, wherein the single chain antibody is selected from the group consisting of CD30, EpCAM (CD326), CD9, Thy-1 (CD90), SSEA-3, SSEA-4, TRA-1-60 or TRA-1-81. The transduction according to the present invention does not interfere with the pluripotency, i.e.

Abstract: The invention relates to recombinant oncolytic viruses that target tumor stem cells and various uses of these recombinant viruses. In particular, an oncolytic virus comprising a recombinant binding domain specific for a tumor stem cell marker is disclosed. Furthermore, the use of such oncolytic viruses for the treatment of cancer is disclosed.

Abstract: The invention relates to a method for identifying stabilizing amino acids in single chain antibody fragments.

Abstract: The present invention relates to a combination of one or more nucleic acids encoding, (a) in a first open reading frame (i) a promoter, (U) an amyloid peptide, (iii) a cell surface targeting signal, (iv) a transmembrane anchoring domain and (b) in a second open reading frame (i) a group specific antigen (gag). Also the invention relates to a pharmaceutical composition and a vaccine comprising A?-retrop articles.

Abstract: A chair includes a base structure and a seat which is movably secured to the base structure. Connected to the seat is a backrest for swinging in a virtually wall-avoiding manner. A footrest is movable between a stowed position when not being used and an extended position when in use, wherein the footrest is disposed in the stowed position below the seat in approximate parallel relationship thereto and has a seat-distal surface provided with a padding. The footrest is connected to the seat by a swivel fitting which is constructed such that a movement of the backrest causes a movement of the footrest.

Abstract: The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus Morbillivirus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation of morbillivirus F and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.